Tesamorelin Regulatory Status: FDA Approval and Compounding Context

Why tesamorelin’s story is different from most peptides Halftime Health discusses.

TL;DR

Tesamorelin is FDA-approved as the brand Egrifta, for one specific condition: HIV-associated lipodystrophy (in plain English: abnormal fat buildup linked to HIV treatment). A compounded version is not itself FDA-approved. That distinction shapes how physicians should discuss it.

What tesamorelin FDA approval status means

Tesamorelin holds real FDA approval, but only for a narrow use. The Food and Drug Administration (FDA) approved Egrifta in 2010 to reduce excess visceral fat in adults with HIV-associated lipodystrophy. Visceral adipose tissue is fat stored around internal organs, not just under the skin. Outside that approved use, compounded tesamorelin is a separate regulatory category entirely.

How the approval-vs-compounding distinction works

Think of it like a car built at the factory versus one assembled by a local mechanic from the same parts list. Egrifta is the factory-built version: FDA reviewed its manufacturing, testing, and trial data. Compounded tesamorelin is prepared by a licensed pharmacy under the FDA’s 503A framework, using the same active ingredient but without that same agency sign-off on the finished product.

Who asks about it

People managing HIV-related fat redistribution ask about tesamorelin most often. Others ask after hearing about its growth hormone-releasing hormone (GHRH) mechanism for general visceral fat, which is an off-label, unapproved use.

What the research says

Falutz et al., published in the New England Journal of Medicine in 2007, found tesamorelin reduced visceral adipose tissue versus placebo in HIV lipodystrophy patients. MedlinePlus (a National Institutes of Health consumer resource) confirms Egrifta’s approved indication and administration details as of its current listing.

What to know before considering it

Compounded medications are not FDA-approved, regardless of how similar the active ingredient is to an approved drug. Physician evaluation, sourcing transparency, and pharmacy quality practices all matter more with compounded tesamorelin than with Egrifta.

The Halftime POV

We believe patients deserve to know which regulatory category they’re in before starting. That means naming Egrifta’s approval status clearly, and being equally clear when a compounded product isn’t the same thing.

Related reading:

• Tesamorelin: who asks
• Tesamorelin: from HIV lipodystrophy to off-label visceral fat research
• Category framework: who’s affected
• FDA 503A bulks list explained

FAQ

Is tesamorelin FDA approved for visceral fat? Yes, for a specific case. Tesamorelin is FDA-approved as the brand Egrifta to reduce excess visceral fat in adults with HIV-associated lipodystrophy, a condition where the body redistributes fat abnormally. It is not FDA-approved for general fat loss in people without this diagnosis.

What is the regulatory status of compounded tesamorelin? Compounded tesamorelin is prepared by a licensed pharmacy under FDA’s 503A framework, not approved as its own drug product. That means it has not gone through FDA review for safety, effectiveness, and manufacturing consistency the way Egrifta has. Physicians may still prescribe it based on individual patient assessment.

Is compounded tesamorelin the same as Egrifta? They contain the same active peptide, but they are not regulatory equivalents. Egrifta is an FDA-approved, agency-inspected product; compounded tesamorelin is pharmacy-prepared and not independently FDA-approved. Sourcing, purity testing, and oversight can differ between the two.

Why does the approval-vs-compounding distinction matter? It affects what has actually been verified. An approved drug has documented trial data behind its specific use; a compounded version relies on the pharmacy’s quality practices and a clinician’s judgment. Patients deserve to know which one they’re getting.

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Want the latest on peptide regulatory news as it develops? Join the waitlist.

Sources

• Falutz, J. et al. “Effects of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients.” New England Journal of Medicine, 2007.
• MedlinePlus, National Institutes of Health. “Tesamorelin Injection.” medlineplus.gov, accessed 2026.
• U.S. Food and Drug Administration. “Compounding and FDA: Questions and Answers.” fda.gov.
• U.S. Food and Drug Administration. “Bulk Drug Substances Nominated for Use in Compounding Under Section 503A.” fda.gov.